KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Common Equity (2016 - 2025)

Historic Common Equity for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • West Pharmaceutical Services' Common Equity rose 1087.9% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 1087.9%. This contributed to the annual value of $2.7 billion for FY2024, which is 689.69% down from last year.
  • West Pharmaceutical Services' Common Equity amounted to $3.1 billion in Q3 2025, which was up 1087.9% from $2.9 billion recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year Common Equity high stood at $3.1 billion for Q3 2025, and its period low was $1.8 billion during Q1 2021.
  • For the 5-year period, West Pharmaceutical Services' Common Equity averaged around $2.6 billion, with its median value being $2.7 billion (2024).
  • As far as peak fluctuations go, West Pharmaceutical Services' Common Equity surged by 2812.26% in 2021, and later tumbled by 689.69% in 2024.
  • West Pharmaceutical Services' Common Equity (Quarter) stood at $2.3 billion in 2021, then increased by 14.97% to $2.7 billion in 2022, then grew by 7.3% to $2.9 billion in 2023, then dropped by 6.9% to $2.7 billion in 2024, then grew by 13.76% to $3.1 billion in 2025.
  • Its Common Equity was $3.1 billion in Q3 2025, compared to $2.9 billion in Q2 2025 and $2.7 billion in Q1 2025.